Prognostic Analysis

Fillmore has focused on identifying accessible biomarkers and clinical indices to improve risk stratification in patients with hematologic and cutaneous malignancies. His research demonstrates that baseline hematologic abnormalities, including thrombocytopenia, lymphopenia, and abnormal monocyte counts, serve as independent predictors of inferior overall survival in multiple myeloma. Additionally, he has established that frailty and the use of potentially inappropriate medications are significant prognostic indicators across various cancers, suggesting that integrating these physiological measures into standard risk models enhances prognostic accuracy.